社区精神分裂症患者用药现状调查与分析
|
摘要
目的了解社区精神分裂症患者用药现状,旨在为相关决策提供参考。方法利用医院信息系统导出2018年1月至2018年10月我社区精神分裂症患者处方100张,利用自行设计的工作表格对社区精神分裂症患者处方进行调查与分析。结果本组抗精神病药物使用频率以非典型抗精神病药为主,以抗癫痫药为次;本组抗精神病药物使用频率以单一用药和两种联合用药为主,三种联合用药、四种联合用药和五种联合用药为次。本组辅助药物使用情况以无辅助药物为主,单一辅助用药为次;辅助药物使用频率顺序排行前5分别为葡醛内酯片、石杉碱甲胶囊、脑蛋白水解物片、维生素B1片及肌苷片。年龄≤44周岁处方金额显著低于年龄>44周岁,差异具有统计学意义(P <0.05)。男性处方金额显著低于女性,差异具有统计学意义(P <0.05)。辅助用药处方金额显著高于无辅助用药,差异具有统计学意义(P <0.05)。结论非典型抗精神病药为精神病药物的主流用药,辅助药物使用合理,处方金额与性别、年龄及辅助用药密切相关。
Objective To understand the current situation of drug use of schizophrenic patients in community, in order to provide reference for relevant decision-making. Methods The hospital information system was used to derive 100 prescriptions for schizophrenia patients from January 2018 to October 2018 in our community, and a self-designed work form was used to investigate and analyze the prescriptions for community schizophrenia patients. Results The use frequency of antipsychotics in this group was mainly atypical antipsychotics, followed by antiepileptic drugs. The use frequency of antipsychotic drugs in this group was mainly single drug and two combined drugs, followed by three combined drugs, four combined drugs and five combined drugs. The use of auxiliary drugs in this group was mainly non-auxiliary drugs, and single auxiliary drug was the second. The top 5 in the order of using auxiliary drugs were glucurolactone tablets, huperzine A capsules, cerebral protein hydrolysate tablets, vitamin B1 tablets and inosine tablets. The amount of prescription under age ≤ 44 was significantly lower than that under age > 44, with statistically significant difference(P <0.05). The amount of prescription for men was significantly lower than that for women, with statistically significant difference(P <0.05). The amount of supplementary medication prescription was significantly higher than that without supplementary medication, with statistically significant difference(P <0.05). Conclusions Atypical antipsychotic drugs are the mainstream of antipsychotic drugs, and the use of auxiliary drugs is reasonable. The amount of prescription is closely related to gender, age and auxiliary drugs.
Objective To understand the current situation of drug use of schizophrenic patients in community, in order to provide reference for relevant decision-making. Methods The hospital information system was used to derive 100 prescriptions for schizophrenia patients from January 2018 to October 2018 in our community, and a self-designed work form was used to investigate and analyze the prescriptions for community schizophrenia patients. Results The use frequency of antipsychotics in this group was mainly atypical antipsychotics, followed by antiepileptic drugs. The use frequency of antipsychotic drugs in this group was mainly single drug and two combined drugs, followed by three combined drugs, four combined drugs and five combined drugs. The use of auxiliary drugs in this group was mainly non-auxiliary drugs, and single auxiliary drug was the second. The top 5 in the order of using auxiliary drugs were glucurolactone tablets, huperzine A capsules, cerebral protein hydrolysate tablets, vitamin B1 tablets and inosine tablets. The amount of prescription under age ≤ 44 was significantly lower than that under age > 44, with statistically significant difference(P <0.05). The amount of prescription for men was significantly lower than that for women, with statistically significant difference(P <0.05). The amount of supplementary medication prescription was significantly higher than that without supplementary medication, with statistically significant difference(P <0.05). Conclusions Atypical antipsychotic drugs are the mainstream of antipsychotic drugs, and the use of auxiliary drugs is reasonable. The amount of prescription is closely related to gender, age and auxiliary drugs.
引文
[1]杨涛,田博,武春建.精神分裂症阴性症状发病机制及治疗的研究进展[J].神经疾病与精神卫生, 2014, 14(3):309-312.
[2]陆丽,施懿凌.精神分裂症发病机制及治疗靶点的研究现状[J].医学综述, 2015, 21(9):1586-1588.
[3]王真真,张有志,李云峰.抗精神分裂症药物的研究进展[J].军事医学, 2013, 37(8):628-631.
[4]许秀峰.单一用药是精神分裂症药物治疗的主流[J].中华精神科杂志, 2014, 47(3):177-178.
[5]戴云飞,肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较[J].临床精神医学杂志, 2013, 23(6):426-427.
[6]刘艳杰,李琳,吴烨青.《医院处方点评管理规范(试行)》执行中存在问题的思考[J].中国药业, 2013, 22(8):70-71.
[7]刘凌云.《医院处方点评管理规范(试行)》执行中的难点及对判定标准的探讨[J].中国医院用药评价与分析, 2016, 16(1):107-110.
[2]陆丽,施懿凌.精神分裂症发病机制及治疗靶点的研究现状[J].医学综述, 2015, 21(9):1586-1588.
[3]王真真,张有志,李云峰.抗精神分裂症药物的研究进展[J].军事医学, 2013, 37(8):628-631.
[4]许秀峰.单一用药是精神分裂症药物治疗的主流[J].中华精神科杂志, 2014, 47(3):177-178.
[5]戴云飞,肖泽萍.中国精神障碍分类与诊断标准第3版与国际疾病分类第10版的比较[J].临床精神医学杂志, 2013, 23(6):426-427.
[6]刘艳杰,李琳,吴烨青.《医院处方点评管理规范(试行)》执行中存在问题的思考[J].中国药业, 2013, 22(8):70-71.
[7]刘凌云.《医院处方点评管理规范(试行)》执行中的难点及对判定标准的探讨[J].中国医院用药评价与分析, 2016, 16(1):107-110.